Eisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These investigational data include a late-breaking oral presentation from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) (NCT02811861) (Abstract # 269) evaluating KEYTRUDA plus LENVIMA and LENVIMA plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Additional data to be presented include two abstracts from Study 218 (NCT03173560), which is a Phase 2 trial evaluating the safety and efficacy of two starting doses of LENVIMA (18 mg versus 14 mg once daily) plus everolimus (5 mg once daily) in patients with advanced RCC. These include a health-related quality of life outcomes analysis (Abstract # 314) as well as efficacy analyses by independent imaging review, and by subgroup of patients who received prior anti-PD-1/L1 therapy per investigator assessment (Abstract # 307). A Trial in Progress abstract will also be presented on a Phase 3 study (NCT04586231) exploring the efficacy and safety of LENVIMA plus the hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor belzutifan (MK-6482) versus cabozantinib in patients with advanced RCC who received prior anti-PD-1/L1 therapy (Abstract #TPS372). In March 2018, Eisai and Merck (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA and Merck's HIF-2a inhibitor, belzutifan. To date, 20 trials have been initiated under the LEAP (LEnvatinib And Pembrolizumab) clinical program, which is evaluating the KEYTRUDA plus LENVIMA combination across 13 different tumor types. For more information on the LEAP program, This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.